Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Milton S. Hershey Medical Center
National Cancer Institute (NCI)
Children's National Research Institute
Children's National Research Institute
National Cancer Institute (NCI)
Emory University
Universitätsklinikum Hamburg-Eppendorf
Bayer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
National Cancer Institute (NCI)
Children's Oncology Group
Emory University
Children's Oncology Group
Emory University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Institutes of Health Clinical Center (CC)
Novartis
Children's Oncology Group
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
St. Jude Children's Research Hospital